Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

  • Sara Carucci, University of Cagliari, AO Brotzu
  • ,
  • Carla Balia, University of Cagliari, AO Brotzu
  • ,
  • Antonella Gagliano, University of Cagliari, AO Brotzu
  • ,
  • Angelico Lampis, AO Brotzu
  • ,
  • Jan K. Buitelaar, Radboud University Medical Centre, Nijmegen, The Netherlands, Karakter Child and Adolescent Psychiatry
  • ,
  • Marina Danckaerts, KU Leuven
  • ,
  • Ralf W. Dittmann, Heidelberg University 
  • ,
  • Peter Garas, Semmelweis University
  • ,
  • Chris Hollis, University of Nottingham
  • ,
  • Sarah Inglis, University of Dundee
  • ,
  • Kerstin Konrad, RWTH Aachen University, Jülich Research Centre
  • ,
  • Hanna Kovshoff, University of Southampton
  • ,
  • Elizabeth B. Liddle, University of Nottingham
  • ,
  • Suzanne McCarthy, University College Cork
  • ,
  • Peter Nagy, Vadaskert Child and Adolescent Psychiatric Hospital
  • ,
  • Pietro Panei, Istituto Superiore di Sanita
  • ,
  • Roberta Romaniello, University of Cagliari
  • ,
  • Tatiana Usala, ATS Sardegna - ASSL Oristano
  • ,
  • Ian C.K. Wong, University College London, University of Hong Kong
  • ,
  • Tobias Banaschewski, Heidelberg University 
  • ,
  • Edmund Sonuga-Barke, King's College London
  • ,
  • David Coghill, University of Melbourne, Murdoch Children's Research Institute, University of Dundee
  • ,
  • Alessandro Zuddas, University of Cagliari, AO Brotzu
  • ,
  • the ADDUCE Consortium

Background: Methylphenidate (MPH) is an efficacious treatment for ADHD but concerns have been raised about potential adverse effects of extended treatment on growth. Objectives: To systematically review the literature, up to December 2018, conducting a meta-analysis of association of long-term (> six months) MPH exposure with height, weight and timing of puberty. Results: Eighteen studies (ADHD n = 4868) were included in the meta-analysis. MPH was associated with consistent statistically significant pre-post difference for both height (SMD = 0.27, 95% CI 0.16-0.38, p < 0.0001) and weight (SMD = 0.33, 95% CI 0.22-0.44, p < 0.0001) Z scores, with prominent impact on weight during the first 12 months and on height within the first 24-30 months. No significant effects of dose, formulation, age and drug-naïve condition as clinical moderators were found. Data on timing of puberty are currently limited. Conclusions: Long-term treatment with MPH can result in reduction in height and weight. However, effect sizes are small with possible minimal clinical impact. Long-term prospective studies may help to clarify the underlying biological drivers and specific mediators and moderators.

OriginalsprogEngelsk
TidsskriftNeuroscience and Biobehavioral Reviews
Vol/bind120
Sider (fra-til)509-525
Antal sider17
ISSN0149-7634
DOI
StatusUdgivet - jan. 2021

Se relationer på Aarhus Universitet Citationsformater

ID: 213356688